{
    "clinical_study": {
        "@rank": "10036", 
        "arm_group": [
            {
                "arm_group_label": "Aldoxorubicin", 
                "arm_group_type": "Experimental", 
                "description": "Aldoxorubicin is administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously on Day 1 every 21-day cycles until tumor progression or unacceptable toxicity occurs."
            }, 
            {
                "arm_group_label": "Investigator's Choice of Treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "These treatments include:\nDacarbazine administered at 1000 mg/m2 by intravenous infusion (IVI), over 90\u00b115 minutes on Day 1 every 21 days until tumor progression or unacceptable toxicity occurs;\nPazopanib, 800 mg orally each day until tumor progression or unacceptable toxicity occurs;\nGemcitabine, 900 mg/m2 by IVI over 90 minutes on Days 1 and 8, plus docetaxel, 100 mg/m2 by IVI over 1 hour on Day 8 of a 28 day cycle until tumor progression or unacceptable toxicity occurs;\nDoxorubicin, 75 mg/m2 by IVI over 5 to 30 minutes every 21 days for a maximum cumulative dose of 550 mg/m2 or unacceptable toxicity occurs; or\nIfosfamide 2.0 g/m2 administered over 2 to 4 hours on Days 1-4 of a 21 day cycle + mesna per standard site administration regimen until tumor progression or unacceptable toxicity occurs."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the efficacy and safety of aldoxorubicin in\n      subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas."
        }, 
        "brief_title": "Phase 3 Study to Treat Patients With Soft Tissue Sarcomas", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma", 
        "condition_browse": {
            "mesh_term": "Sarcoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Has provided written informed consent prior to any study related activities.\n\n          2. Age \u226515 years (US only), and 18-80 (rest of world (ROW)), male or female.\n\n          3. Histological confirmation of intermediate or high grade soft-tissue sarcoma. Tissue\n             must be sent to a central pathology lab for review but will not preclude entry onto\n             the study. Final assignment of tumor grade and histology will be based on the\n             designation provided by the central pathology review.\n\n          4. An adequate tumor specimen obtained by either excisional biopsy, incisional biopsy or\n             core needle biopsy must be sent to the central pathology lab for evaluation. The\n             material must measure at least 0.8 \u00d7 0.1 cm in size or contain at least 50 tumor\n             cells.\n\n          5. Locally advanced, unresectable, and/or metastatic soft-tissue sarcoma of intermediate\n             or high grade with evidence of disease progression by either computed tomography (CT)\n             or magnetic resonance imaging (MRI) scan, or clinical judgment on or after the last\n             cancer therapy within 6 months prior to randomization.\n\n          6. Relapsed or refractory (lack of response) to \u22651 course of systemic therapy\n             regimen(s), excluding adjuvant or neoadjuvant chemotherapy, and is incurable by\n             either surgery or radiation.\n\n          7. Capable of providing informed consent and complying with trial procedures.\n\n          8. ECOG PS 0-2.\n\n          9. Life expectancy >12 weeks.\n\n         10. Measurable tumor lesions according to RECIST 1.1 criteria.[50]\n\n         11. Women must not be able to become pregnant (e.g., post-menopausal for at least 1 year,\n             surgically sterile, or practicing adequate birth control methods) for the duration of\n             the study. (Adequate contraception includes: oral contraception, implanted\n             contraception, intrauterine device implanted for at least 3 months, or barrier method\n             in conjunction with spermicide.)\n\n         12. Males and their female partner(s) of child-bearing potential must use 2 forms of\n             effective contraception (see Inclusion 11 plus condom or vasectomy for males) from\n             the last menstrual period of the female partner during the study treatment and agree\n             to continue use for 6 months after the final dose of study treatment.\n\n         13. Women of child bearing potential must have a negative serum or urine pregnancy test\n             at the Screening Visit and be non-lactating.\n\n         14. Accessibility to the site that optimizes the subject's ability to keep all\n             study-related appointments.\n\n        Exclusion Criteria:\n\n          1. Prior exposure to >375 mg/m2 of doxorubicin or liposomal doxorubicin.\n\n          2. Palliative surgery and/or radiation treatment within 30 days prior to date of\n             randomization.\n\n          3. Exposure to any investigational agent within 30 days of date of randomization.\n\n          4. Exposure to any systemic chemotherapy within 30 days of date of randomization.\n\n          5. An inadequate tumor specimen as defined by the central pathologist.\n\n          6. Current evidence/diagnosis of alveolar soft part sarcoma, extraskeletal myxoid\n             chondrosarcoma, rhabdomyosarcoma, osteosarcoma, gastrointestinal stromal tumor\n             (GIST), dermatofibrosarcoma (unless transformed to fibrosarcoma), Ewing's sarcoma,\n             Kaposi's sarcoma, mixed mesodermal tumor, clear cell sarcomas.\n\n          7. Evidence of central nervous system (CNS) metastasis who have not received prior\n             definitive therapy for their lesions.\n\n          8. History of other malignancies except cured basal cell carcinoma, cutaneous squamous\n             cell carcinoma, melanoma in situ, superficial bladder cancer or carcinoma in situ of\n             the cervix unless documented free of cancer for \u22655 years.\n\n          9. Laboratory values: Screening serum creatinine >1.5 x upper limit of normal (ULN),\n             alanine aminotransferase (ALT) >3\u00d7ULN or >5\u00d7ULN if liver metastases are present,\n             total bilirubin >2\u00d7ULN, absolute neutrophil count (ANC) <1,500/mm3, platelet\n             concentration <100,000/mm3, hemoglobin <9g/dL.\n\n         10. Clinically evident congestive heart failure (CHF) > class II of the New York Heart\n             Association (NYHA) guidelines.\n\n         11. Current, serious, clinically significant cardiac arrhythmias, defined as the\n             existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown\n             III, IV or V.\n\n         12. Baseline QTc >470 msec and/or previous history of QT prolongation while taking other\n             medications.\n\n         13. Concomitant use of medications associated with a high incidence of QT prolongation is\n             not allowed.\n\n         14. History or signs of active coronary artery disease with or without angina pectoris\n             within the last 6 months.\n\n         15. Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection\n             fraction (LVEF) below the institution's lower limit of predicted normal.\n\n         16. Known history of HIV infection.\n\n         17. Active, clinically significant serious infection requiring treatment with\n             antibiotics, anti-virals or anti-fungals. The Medical Monitor should be contacted for\n             any uncertainties.\n\n         18. Major surgery within 30 days prior to date of randomization.\n\n         19. Current or past substance abuse or any condition that might interfere with the\n             subject's participation in the study or in the evaluation of the study results.\n\n         20. Any condition that is unstable and could jeopardize the subject's participation in\n             the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02049905", 
            "org_study_id": "ALDOXORUBICIN-P3-STS-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aldoxorubicin", 
                "intervention_name": "Aldoxorubicin", 
                "intervention_type": "Drug", 
                "other_name": "INNO-206"
            }, 
            {
                "arm_group_label": "Investigator's Choice of Treatment", 
                "intervention_name": "Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Darcabazine", 
                    "Pazopanib", 
                    "Gemcitabine + Docetaxel", 
                    "Doxorubicin", 
                    "Ifosfamide"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Isophosphamide mustard", 
                "Gemcitabine", 
                "Docetaxel", 
                "Ifosfamide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "soft tissue sarcoma", 
            "unresectable", 
            "metastatic", 
            "locally advanced", 
            "sarcoma"
        ], 
        "lastchanged_date": "May 9, 2014", 
        "location": [
            {
                "contact": {
                    "email": "andrea.mcneill@usoncology.com", 
                    "last_name": "Andrea McNeill", 
                    "phone": "602-274-5141"
                }, 
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85016"
                    }, 
                    "name": "Arizona Oncology Associates, PC"
                }, 
                "investigator": {
                    "last_name": "Mahesh Seetharam, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "vchua@sarcomaoncology.com", 
                    "last_name": "Vicky Chua", 
                    "phone": "310-552-9999"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "940403"
                    }, 
                    "name": "Sarcoma Oncology Center"
                }, 
                "investigator": {
                    "last_name": "Sant Chawla, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "JC Ramirez", 
                    "phone": "650-725-7760"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Karen Ganjoo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jputhenveetil@oncmed.net", 
                    "last_name": "James Puthenveetil", 
                    "phone": "847-410-0659"
                }, 
                "facility": {
                    "address": {
                        "city": "Niles", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60714"
                    }, 
                    "name": "Oncology Specialists, SC"
                }, 
                "investigator": {
                    "last_name": "Pamela Kaiser, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kathryn.murray@uvm.edu", 
                    "last_name": "Kathryn Murray", 
                    "phone": "802-656-9401"
                }, 
                "facility": {
                    "address": {
                        "city": "Burlington", 
                        "country": "United States", 
                        "state": "Vermont", 
                        "zip": "05405"
                    }, 
                    "name": "Fletcher Allen Health Care"
                }, 
                "investigator": {
                    "last_name": "Claire Verschraegen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gabor.kozma@coordination.hu", 
                    "last_name": "Gabor Kozma"
                }, 
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Magyar Honvedseg Egeszsegugyi Kozpont"
                }, 
                "investigator": {
                    "last_name": "Zsuzsanna Papai, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Hungary"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PFS is defined as the time from the date of randomization to first documentation of objective tumor progression or to death due to any cause in the absence of previous documentation of objective tumor progression.", 
            "measure": "Progression-Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02049905"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall survival is defined as the time from randomization to date of death.  In the absence of confirmation of death, survival time will be censored at the last date the subject is known to be alive.", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "The safety of aldoxorubicin compared to investigator's choice in this population assessed by the frequency and severity of adverse events (AEs), abnormal findings on physical examination, laboratory tests, vital signs, echocardiogram (ECHO) evaluations, electrocardiogram (ECG) results, and weight, as well as disease control rate and tumor response.", 
                "measure": "Safety Measures", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "source": "CytRx", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CytRx", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}